Identifying Undiagnosed HFpEF Among Patients With Type 2 Diabetes Using Ultromics AI HFpEF Algorithm
University of Texas Southwestern Medical Center
Summary
A pragmatic electronic health record (EHR) based randomized controlled trial to evaluate the utility of providing Ultromics EchoGo analysis results and recommendations for HF risk prevention therapies using an EHR embedded clinical decision support tool.
Description
Historic echocardiograms will be analyzed using the Ultromics EchoGo algorithm. For patients that have a positive EchoGO result i.e. HFpEF detected, the provider will get an clinical decision support alert flagging high risk of HFpEF based on randomized assignment. Experimental: Alert Group Provider will receive a computer-based provider-to-provider message notifying the provider that the patient has subclinical HFpEF as determined by the Ultromics EchoGo algorithm and associated guideline recommendations for the management of these patients. The alert will include guideline-based and standar…
Eligibility
- Age range
- Not specified
- Sex
- All
- Healthy volunteers
- No
Clinical cohort inclusion exclusion criteria: Inclusion Criteria: * Patients with diagnosis of Type 2 diabetes and High WATCH DM score. * Echocardiogram available in last 6-months. Exclusion Criteria: * History of HF * Not eligible for prescription of new GLP-1RA or SGLT2i or ns-MRA Corresponding providers to patients identified by the above inclusion exclusion criteria will be included in the clinical trial of the decision support tool.
Interventions
- BehavioralMessage with EchoGo
This alert will inform the provider that the patient has subclinical HFpEF
- BehavioralStandard Message
This alert will inform the provider of guideline directed treatment options for patients with diabetes to prevent heart failure.
Location
- UT Southwestern Medical CenterDallas, Texas